We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Fractyl Health Inc | NASDAQ:GUTS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.48 | 11.24% | 4.75 | 4.37 | 4.75 | 4.69 | 4.25 | 4.39 | 242,044 | 22:42:26 |
The abstract, “Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity” was recognized as noteworthy and selected by the Scientific Sessions Meeting Planning Committee as one of eight Presidents’ Select abstracts and will be presented first in the poster session, “Weighing Opportunities of Incretin-Based Therapy in Obesity.”
Details of the presentation are provided below.
KOL Event:
Fractyl Health will host an in-person Key Opinion Leader (KOL) event during the ADA’s 84th Scientific Sessions. The event will take place on Monday, June 24, 2024, from 7:00 a.m. – 8:00 a.m. ET at the Hilton Orlando Hotel in Orlando, FL.
The event will feature Dr. David A. D’Alessio (Duke University School of Medicine), who will provide insights on the unmet medical need and evolving treatment landscape for patients with obesity and T2D. In addition, members of Fractyl management will discuss the Company’s two novel platforms, Revita® and Rejuva, and their potential to be a single-administration disease-modifying solution.
A question-and-answer session will follow the formal presentation. For those who are unable to attend in person, a live webcast of the event will be available in the “Events” section of Fractyl’s website at www.ir.fractyl.com.
About David A. D’Alessio, M.D.
Dr. D’Alessio is the James B. Wyngaarden Distinguished Professor of Medicine; Professor of Medicine; Chief, Division of Endocrinology and Metabolism; and Member of Duke Molecular Physiology Institute, all at Duke University School of Medicine. Dr. D’Alessio has a primary research interest in the regulation of glucose tolerance and abnormalities that lead to T2D. Work in his lab is directed at the interplay of circulating glucose, GI hormones and neural signals to control insulin secretion. The focus is the gut peptide GLP-1 and its role in normal physiology, T2D and bariatric surgery.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth.
About Rejuva Fractyl Health’s Rejuva® platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.
Contacts
Corporate Contact Lisa Davidson, Chief Financial Officer ir@fractyl.com, 781.902.8800
Media Contact Jessica Cotrone, Corporate Communications jcotrone@fractyl.com, 978.760.5622
Investor Contact Stephen Jasper Gilmartin Group stephen@gilmartinir.com, 619.949.3681
1 Year Fractyl Health Chart |
1 Month Fractyl Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions